Related Experiment Video
Updated: Sep 20, 2026
Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes
Published on: May 23, 2025
RAF antisense oligonucleotide as a tumor radiosensitizer
Usha Kasid1, Anatoly Dritschilo
1Department of Radiation Medicine, Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC 20007, USA.
Abstract:
The RAF-1 serine-threonine kinase plays a central role in signal transduction pathways involved in cell survival and proliferation. The concept of RAF-1-targeted disruption of cell signaling for therapeutic purposes was first advanced in 1989 with the demonstration of tumor growth inhibition in athymic mice and radiosensitization of human squamous carcinoma cells transfected with a vector expressing antisense cDNA. However, the clinical application of antisense strategies has awaited the development of improved antisense oligonucleotide technologies and drug delivery methods. Nuclease-resistant phosphorothioated antisense oligonucleotides have been the focus of pharmaceutical industry attention. In vivo delivery of nuclease-sensitive, natural backbone/phosphodiester oligonucleotides has remained a formidable challenge. Liposomal encapsulation of antisense oligonucleotides protects them from degradation and enhances drug delivery. Here, we review the importance of targeting RAF-1 signaling in cancer therapy and the preclinical and clinical experiences with a liposomal formulation of a nuclease-sensitive, ends-modified antisense RAF oligonucleotide.
Insights
Targeting RAF-1 signaling with antisense oligonucleotides shows promise for cancer therapy. Liposomal encapsulation improves delivery and stability, overcoming previous challenges for clinical application.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- RAF-1 kinase is crucial in cell survival and proliferation signaling pathways.
- Targeting RAF-1 has been explored for cancer therapy since 1989, demonstrating tumor inhibition.
- Clinical application of antisense strategies was limited by technology and delivery challenges.
Purpose of the Study:
- To review the significance of targeting RAF-1 signaling in cancer.
- To discuss preclinical and clinical data of a liposomal antisense RAF oligonucleotide.
Main Methods:
- Review of literature on RAF-1 signaling and antisense oligonucleotide technology.
- Evaluation of liposomal encapsulation as a drug delivery method for antisense oligonucleotides.
- Analysis of preclinical and clinical studies involving a specific liposomal formulation.
Main Results:
- Liposomal encapsulation protects nuclease-sensitive oligonucleotides from degradation.
- Improved delivery and stability of antisense oligonucleotides enhance therapeutic potential.
- Preclinical and clinical data support the efficacy of liposomal antisense RAF oligonucleotide.
Conclusions:
- Targeting RAF-1 signaling is a viable strategy for cancer treatment.
- Liposomal delivery systems overcome major hurdles for antisense oligonucleotide therapy.
- Further clinical development of liposomal antisense RAF oligonucleotides is warranted.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:15Experimental RNAi